The Creech Research Team focuses primarily on the growing problem of methicillin-resistant Staphylococcus aureus (MRSA). The group is currently conducting studies aimed at understanding the epidemiology of nasal colonization in pregnant women, newborns and collegiate athletes, and at evaluating new antimicrobials and candidate staphylococcal vaccines in clinical trials.
Dr. Halasa's research interest lies in studying respiratory infections in specialized populations. Her recent work has focused on immunization of neonates with pertussis vaccine, as well as investigating the safety and immunogenicity of the administration of the influenza vaccine in infants 10-22 weeks of age. Dr. Halasa also participates in multi-center vaccines trials with respiratory viral vaccines. Learn more about Dr. Halasa's research.
The Vanderbilt Vaccine Research program is one of only eight Vaccine Treatment and Evaluation Units in the country to receive a new contract to continue evaluating innovative vaccines for malaria, pandemic flu and other infections over the next seven years. The program has been recognized internationally for its work on vaccines against serious childhood infections including respiratory syncytial virus and haemophilius influenzae and has demonstrated exceptional experience and expertise in vaccine science and great capacity to recruit volunteers from the community.